Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Rakhi Kumar Sells 227,500 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CAO Rakhi Kumar sold 227,500 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the sale, the chief accounting officer now directly owns 163,264 shares in the company, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $10.68 on Wednesday. Roivant Sciences Ltd. has a 1 year low of $9.76 and a 1 year high of $13.06. The company has a market capitalization of $7.77 billion, a PE ratio of 1.89 and a beta of 1.25. The company has a fifty day moving average of $11.31 and a 200 day moving average of $11.59.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%. Research analysts expect that Roivant Sciences Ltd. will post -1.19 earnings per share for the current year.

Institutional Investors Weigh In On Roivant Sciences

Several hedge funds have recently bought and sold shares of ROIV. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Roivant Sciences by 4.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,411,466 shares of the company’s stock valued at $28,528,000 after purchasing an additional 104,288 shares in the last quarter. Zimmer Partners LP purchased a new position in Roivant Sciences in the fourth quarter valued at $2,992,000. Vestal Point Capital LP purchased a new position in Roivant Sciences in the fourth quarter valued at $14,788,000. Vident Advisory LLC raised its position in shares of Roivant Sciences by 98.7% in the fourth quarter. Vident Advisory LLC now owns 32,039 shares of the company’s stock worth $379,000 after acquiring an additional 15,918 shares during the period. Finally, Tyro Capital Management LLC boosted its stake in shares of Roivant Sciences by 20.1% during the 4th quarter. Tyro Capital Management LLC now owns 2,108,283 shares of the company’s stock worth $24,941,000 after acquiring an additional 353,307 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Roivant Sciences has a consensus rating of “Buy” and a consensus target price of $18.08.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.